What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Parkinson's Disease Clinical Trials 2026: New Treatments and How to Enroll

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Parkinson's disease research has entered one of its most active periods in decades. In 2026, over 400 clinical trials are actively recruiting patients — ranging from gene therapies targeting dopamine-producing neurons to antibodies against alpha-synuclein, the protein that forms toxic clumps in Parkinson's brains. GLP-1 drugs, already approved for diabetes and obesity, are also being tested for neuroprotection. This guide explains what's available and how to find a trial.

The Most Promising Approaches in 2026

Alpha-synuclein targeting: The accumulation of misfolded alpha-synuclein (Lewy bodies) is central to Parkinson's pathology. Multiple antibodies — prasinezumab (Roche), buntanetap (Annovis Bio) — are in Phase 2/3 trials attempting to clear or prevent this buildup. Results from the PASADENA and SPARK trials are shaping next-generation trial designs.

Gene therapy: AAV-based gene therapies delivered directly into the brain are in Phase 1/2 trials. Approaches include restoring dopamine synthesis (AADC gene therapy — already approved in Europe for aromatic L-amino acid decarboxylase deficiency), and neuroprotective approaches using GDNF (glial cell line-derived neurotrophic factor).

GLP-1 neuroprotection: Semaglutide and liraglutide are in Phase 2 trials (SPARK-PD, Liraglutide in Parkinson's) based on observational data showing lower Parkinson's incidence in diabetic patients taking GLP-1 drugs. The mechanism may involve reducing neuroinflammation and oxidative stress.

Focused ultrasound: MRI-guided focused ultrasound (MRgFUS) is FDA-approved for essential tremor and now in trials for Parkinson's tremor and dyskinesia. It's non-invasive, targeting the thalamus or subthalamic nucleus without surgery.

Who Is Eligible for Parkinson's Trials

Eligibility varies significantly by trial type. Disease-modifying trials (targeting alpha-synuclein, gene therapy) typically enroll:

Early-stage Parkinson's (Hoehn & Yahr stage 1–2.5), often within 2–3 years of diagnosis
Age 40–80 (varies by protocol)
No cognitive impairment (MoCA ≥24 in most trials)
Genetic biomarker trials may require LRRK2 or GBA mutations — genetic testing is often provided at screening

Symptomatic treatment trials (for motor fluctuations, dyskinesia, freezing of gait) typically accept more advanced disease. Neuroprotection trials (GLP-1) are often open to a wider range of stages.

LRRK2 and GBA: Why Genetics Matter

Approximately 10–15% of Parkinson's cases have a known genetic cause. The most common genetic variants are LRRK2 (leucine-rich repeat kinase 2) mutations and GBA (glucocerebrosidase) variants. Several trials are specifically targeting these pathways — LRRK2 inhibitors (DNL201, BIIB122) are in Phase 2, and substrate reduction therapies for GBA-Parkinson's are actively recruiting.

If you have Parkinson's and haven't had genetic testing, ask your neurologist about it. A positive result can open additional trial options and often provides important prognostic information.

How to Find and Join a Trial

Search ClinicalTrials.gov using terms like "Parkinson disease" with status filter "Recruiting." The Michael J. Fox Foundation's Fox Trial Finder is specifically designed for Parkinson's patients and matches you to studies based on your profile, location, and disease characteristics. The Parkinson's Foundation also maintains a trial listing at parkinson.org.

For gene therapy and surgical trials, major academic medical centers (UCSF, Mayo Clinic, Johns Hopkins, UCL in London) are typically the enrollment sites. Telehealth and hybrid designs are increasingly available for observational and biomarker sub-studies.